ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
June 08, 2021Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Institute, with the ...
Pharma Sources Insight January 2025
